Alligator enters China’s ‘advancing’ market through licensing agreement

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Rainer Puster)
(Image: Getty/Rainer Puster)

Related tags: License, China, Bispecific antibodies, Antibody

Alligator grants Biotheus rights to an antibody for the creation of three bispecific molecules in the Greater China region.

The license agreement will see China-based Biotheus gain rights in the Republic of China, Hong kKong, Taiwan, and Macau to the antibody from Alligator Bioscience’s Alligator-Gold platform. Biotheus will use this antibody to develop three bispecific molecules.

In addition, the licensing agreement includes an option for Biotheus to expand its license to gain global rights to the antibody.

The antibody works against the tumor necrosis factor receptor (TNFR) family, which is a group of related receptors sharing sequence homology.

Per Norlén, CEO of Alligator, said in a statement that this collaboration with the Chinese biotech​ firm gives the company an entry into the “ fast advancing life science market in China.”

Biotheus will pay Alligator $1m (€900,000m) upfront in return for the licensing agreement, with $500,000 due at signing and the other $500,000 paid after six months of scientific and technical evaluation.

Alligator is eligible to receive milestones and option fees up to a total of $142m. If Biotheus chooses to exercise its option to gain global rights, it will pay $90m to Alligator,  plus royalties on future sales and a share of sub-license revenue.

Related news

Show more

Related products

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

Follow us


View more